Mankind Pharma is a pharmaceutical company that develops, commercializes, and delivers medicines for urgent medical needs.
Mankind Pharma aspires to aid the community in a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. Mankind Pharma came into existence in 1986, and in 1991, the company was formed into a legal corporation. However, it actively started working as a fully-integrated pharmaceutical company in 1995. Today, Mankind has an employee base of over 14,000 and is racing towards $1 Billion.The company takes great pride in the success of its products ranging from Pharma, OTC, and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Adiction, Gas-O-Fast, Kaloree 1 and many others.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 28, 2015 | Secondary Market | $215M | 1 |
|
— | Detail |
Apr 30, 2007 | Private Equity(PE) | $24M | 2 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 23, 2022
![]() |
Seed | ₹130M | Energy | — |
Mar 21, 2022
![]() |
Series B | $22M | Artificial Intelligence | — |
Jan 19, 2022
![]() |
Series A | ₹500M | Food and Beverage | Yes |
Aug 11, 2021
![]() |
Series B | ₹2.13B | Artificial Intelligence | Yes |
Jun 9, 2021
![]() |
Angel | — | Consumer Electronics | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
|
Yes | Secondary Market |
![]() |
Yes | Private Equity(PE) |
![]() |
— | Private Equity(PE) |
Mankind Pharma has acquired 2 organizations. Their most recent acquisition was Panacea Biotec Pharma - Formulations business on Feb 1, 2022. They acquired Panacea Biotec Pharma - Formulations business for ₹19.08B.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Feb 1, 2022
![]() |
Biopharma | acquisition | ₹ 19.08B | Detail |
Nov 28, 2022
![]() |
Health Care | acquisition | — | Detail |